Bli medlem
Bli medlem

Du är här

2016-06-01

Galapagos NV: Galapagos creates new warrant plan

Mechelen, Belgium; 1 June 2016 - Galapagos NV (Euronext&NASDAQ: GLPG)
announced today that itsBoard of Directors created 865,000 warrants under new
warrant plans for the
benefit of employees, directors and an independent consultant of the Company
and its subsidiaries.

On 1 June 2016, the Board of Directors of Galapagos approved the "Warrant Plan
2016," a warrant plan intended mainly for employeesof the Company and its
subsidiaries, and also for directors and an independent consultant of the
Company, and the "Warrant Plan 2016 RMV," a warrant plan intended for the
employees of the Company's French subsidiary, Galapagos SASU,within the
framework of the authorized capital. Under these warrant plans, 865,000
warrants were created, subject to acceptances.

The warrants created under Warrant Plan 2016 and Warrant Plan 2016 RMV were
offered on 1 June 2016. The offer of warrants to directors was approved by
the Annual Shareholders' Meeting held on 26 April 2016.

The warrants have an exercise term of eight years as of the date of the offer
and have an exercise price of €46.10 (the average closing price of the share
on Euronext Amsterdam and Brussels during the thirty days preceding the date
of the offer). The warrants are not transferable and can in principle not be
exercised prior to 1 January 2020. Each warrant gives the right to subscribe
to one new Galapagos share. Should the warrants be exercised, Galapagos will
apply for the listing of the resulting new shares on a regulated stock
market. The warrants as such will not be listed on any stock market.

Galapagos' total share capital currently amounts to €249,394,222.78; the total
number of securities conferring voting rights is 46,109,508, which is also
the total number of voting rights (the "denominator"), and all securities
conferring voting rights and all voting rights are of the same category. The
total number of rights (warrants) to subscribe to not yet issued securities
conferring voting rights is 2,981,227, which equals the total number of
voting rights that may result from the exercise of these warrants, and
excludes the 865,000 warrants of Warrant Plan 2016 and Warrant Plan 2016 RMV
which were created subject to acceptances. Galapagos does not have any
convertible bonds or shares without voting rights outstanding.

About Galapagos

Galapagos (Euronext&NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action. Our maturing pipeline comprises Phase 2, Phase 1,
pre-clinical and discovery studies in cystic fibrosis, inflammation,
fibrosis, osteoarthritis and other indications. We have discovered and
developed filgotinib: in collaboration with Gilead we aim to bring this
JAK1-selective inhibitor for inflammatory indications to patients all over
the world. Galapagos is focused on the development and commercialization of
novel medicines that will improve people's lives. The Galapagos group,
including fee-for-service subsidiaryFidelta, has approximately 440 employees,
operating from its Mechelen, Belgium headquarters and facilities in The
Netherlands, France, and Croatia. More information atwww.glpg.com.

CONTACT

------------------------------------------------
| Investors: Media: |
| Elizabeth Goodwin Evelyn Fox |
| VP IR&Corporate Director Communications |
| |
|Communications +31 6 53 591 999 |
|+1 781 460 1784 communications@glpg.com |
| Paul van der Horst |
|Director IR&Business |
|Development |
|+31 6 53 725 199 |
| ir@glpg.com |
------------------------------------------------
Forward-looking statements

This release may contain forward-looking statements, all of which involve
certain risks and uncertainties. These statements are often, but not always,
made through the use of words or phrases such as "anticipates," "believes,"
"continues," "could," "estimates," "expects," "intends," "may," "plans,"
"seeks," "stands to," "we believe," "will," "we intend," as well as similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors which might cause the actual results,
financial condition and liquidity, performance or achievements of Galapagos,
or industry results, to be materially different from any historic or future
results, financial conditions and liquidity, performance or achievements
expressed or implied by such forward-looking statements. In addition, even if
Galapagos' results, performance, financial condition and liquidity, and the
development of the industry in which it operates are consistent with such
forward-looking statements, they may not be predictive of results or
developments in future periods. Among the factors that may result in
differences are the inherent uncertainties associated with competitive
developments, clinical trial and product development activities and
regulatory approval requirements (including that data from Galapagos' ongoing
clinical research programs may not support registration or further
development of its product candidates due to safety, efficacy or other
reasons), Galapagos' reliance on collaborations with third parties, and
estimating the commercial potential of Galapagos' product candidates. A
further list and description of these risks, uncertainties and other risks
can be found in Galapagos' Securities and Exchange Commission (SEC) filings
and reports, including
in Galapagos' most recent annual report on form 20-F filed with the SEC and
subsequent filings and reports filed by Galapagos with the SEC. Given these
uncertainties, the reader is advised not to place any undue reliance on such
forward-looking statements. These forward-looking statements speak only as of
the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based or
that may affect the likelihood that actual results will differ from those set
forth in the forward-looking statements, unless specifically required by law
or regulation.

GLPG creates new warrant plan
http://hugin.info/133350/R/2017386/748534.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Globenewswire

HUG#2017386

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.